Availability of monkeypox vaccinations for low and middle-income countries: Challenges and recommendations

Farahat, Ramadan Abdelmoez; Khan, Sheharyar Hassan; Memish, Ziad A.

doi:10.1016/j.tmaid.2022.102473

Cited by 6 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most cases have just required medications for pain relief and antiviral therapy, while some serious ones landing into encephalitis have required intubation and ventilatory support. Oral antiviral medications for MPX include Cidofovir and Tecovirimat (Farahat et al., 2022 ). Corticosteroids may be considered for an ADEM‐like presentation, keeping in mind the possible immunosuppressive complications (Pastula et al., 2022 ).…”

Section: Evolving Management Strategiesmentioning

confidence: 99%

“…It has been observed that the west African phylogenetic clade of MPX has a lower case fatality rate (3.6%) than the Congo Basin clade (10.6%) (WHO, 2022c ). The World health organization (WHO) has declared the endemic disease of the African tropical rainforest a public health emergency of international concern (Farahat et al., 2022 ; WHO, 2022f ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Neuropsychiatric manifestations of monkeypox: A clinically oriented comprehensive review

et al. 2023

View full text Add to dashboard Cite

Monkeypox (MPX) has emerged as a threatening outbreak in recent months. The understanding of disease pathogenesis and its systemic involvement has evolved with time. Both the virus and its vaccine, like other members of the Orthopoxvirus family, were always expected to have neuropsychiatric consequences. Several neurological complications have been reported with MPX and its vaccines that include but not limited to headaches, myalgia, encephalitis, and coma. Psychiatric complications like anxiety and depression have also been reported; however, we lack evidence to present a direct causality. We conducted a literature review to compile recent evidence on neuropsychiatric manifestations and underline the importance of evolving aspects and complications of MPX. We advocate for better reporting of cases and adverse events, to enhance our understanding of the disease, aiding physicians to make more informed decisions, thus facilitating timely diagnosis and treatment.

show abstract

Section: Evolving Management Strategiesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Neuropsychiatric manifestations of monkeypox: A clinically oriented comprehensive review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The reason of such an abrupt increase in the number of patients with MPX around the world may be due to the fact that the MPX derived from a mutation that allows MPX to transmit more readily than it did in the past. [13] In contrast to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a rapidly evolving RNA virus whose variants have evaded immunity from vaccines and previous infection, MPX is generated by a relatively large DNA virus. [14] It is easier to detect and repair mutations in DNA viruses (i.e., MPXV) than in RNA viruses (i.e., SARS-CoV-2), which indicates that the possibility of the MPXV having a sudden increase in mutations and becoming capable at human-to-human transmission is low.…”

Section: Are There Different Monkeypox Viruses?mentioning

confidence: 99%

Global, regional, and national incidence and mortality of human monkeypox infection in 107 countries and territories, October 2022: a systematic analysis for World Health Organization database and rapid review

Park¹,

Yon²

2022

Life Cycle

View full text Add to dashboard Cite

The monkeypox is an unusual viral disease which, until recently, has rarely been detected outside of Africa. Approximately over 70,000 laboratory-verified or suspected cases of human monkeypox have been discovered in at least 107 countries in a matter of months. A total of 71,237 laboratory confirmed cases, 1,097 probable cases, and 26 related deaths regarding the monkeypox were confirmed worldwide up to October 6th, 2022. Among the six World Health Organization regions, the Americas demonstrated the highest total laboratory-confirmed monkeypox cases (45,342 cases), followed by the European Region (24,889 cases), the African Region (727 cases), the Western Pacific Region (189 cases), the Eastern Mediterranean Region (67 cases), and the South-East Asia Region (23 cases). The nation with the highest cumulative monkeypox cases was the United States of America (26,723 cases), followed by Brazil (8,147 cases), Spain (7,209 cases), France (4,043 cases), The United Kingdom (3,654 cases), and Germany (3,640 cases). This international and comprehensive review, through analysis of the types and differences among the virus, the reason of its epidemic, and current available vaccines, aims to provide crucial information needed for monkeypox research and enhance global health policies in an individual-and country-level strategies towards the treatment of monkeypox.

show abstract

A Multi-pronged Approach to Addressing Global Poxviruses Vaccine Inequity: A Case of Monkeypox

Son,

Wambalaba,

Wambalaba

2024

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Availability of monkeypox vaccinations for low and middle-income countries: Challenges and recommendations

Cited by 6 publications

References 6 publications

Neuropsychiatric manifestations of monkeypox: A clinically oriented comprehensive review

Neuropsychiatric manifestations of monkeypox: A clinically oriented comprehensive review

Global, regional, and national incidence and mortality of human monkeypox infection in 107 countries and territories, October 2022: a systematic analysis for World Health Organization database and rapid review

A Multi-pronged Approach to Addressing Global Poxviruses Vaccine Inequity: A Case of Monkeypox

Contact Info

Product

Resources

About